Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 7, 2026

Top Analyst Reports for Amazon.com, Walmart & American Express

View original at finance.yahoo.com
Top Analyst Reports for Amazon.com, Walmart & American Express Tuesday, July 7, 2026 The Zacks Research Daily presents the best research output of our analyst team…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Key risks for Natural Grocers include softer consumer spending on premium organic products, rising technology and expansion costs, supply-chain and organic sourcing constraints, and intensifying competition from larger retailers; the stock trades at 0.56X trailing 12-month EV/sales.

    60% confidence
  • American Express' shares have outperformed the Zacks Financial - Miscellaneous Services industry over the past year (+13.4% vs. -22%), benefiting from strong spending growth from Millennials and Gen Z, rewards, travel/dining platforms, strategic acquisitions and AI investments.

    60% confidence
  • For 2Q'26, AMZN guided net sales of $194-$199 billion and operating income of $20-$24 billion.

    60% confidence
  • Ampco-Pittsburgh must improve profitability in its core FCEP business and convert backlog into sustainable cash flow; elevated leverage and asbestos liabilities remain overhangs despite improving fundamentals.

    60% confidence
  • Marketplace, advertising and membership are becoming more important profit drivers for Walmart, diversifying earnings; investments in automation and AI should enhance customer experience, efficiency and long-term productivity.

    60% confidence
  • American Express returned $2.3 billion to shareholders in Q1 2026 through dividends and buybacks.

    60% confidence
  • Amazon.com's shares have outperformed the Zacks Internet - Commerce industry over the past year (+12.8% vs. +2.5%), aided by international expansion and diversification across e-commerce, AWS, advertising and streaming.

    60% confidence
  • While fuel costs, currency movements, policy uncertainty and elevated investments may affect Walmart's near-term profitability, its focus on execution, digital expansion and ecosystem growth supports a favorable long-term outlook.

    60% confidence
  • Ampco-Pittsburgh's shares have outperformed the Zacks Metal Products - Procurement and Fabrication industry over the past six months (+39.8% vs. -2.3%), driven by its shift toward higher-value infrastructure markets including nuclear energy, defense and power generation.

    60% confidence
  • Capital expenditure requirements for AI infrastructure and data centers strain Amazon's financial resources and compress margins, with TTM free cash flow decreasing to $1.2 billion; expanding debt burden reduces financial flexibility amid rising interest rates and intensifying competition from Walmart, Microsoft Azure, and Google Cloud is an overhang.

    60% confidence
  • Rising expense intensity, elevated credit-loss provisions amid weakening consumer credit trends, and relatively high leverage could pressure American Express margins and earnings stability; Zacks reiterates a Neutral stance on the stock.

    60% confidence
  • Natural Grocers by Vitamin Cottage's shares have outperformed the Zacks Food - Natural Foods Products industry over the past six months (+38.5% vs. +23.2%), supported by resilient operating performance, positive comparable sales growth and rising loyalty program penetration.

    60% confidence
  • Walmart's shares have outperformed the Zacks Retail - Supermarkets industry over the past year (+17% vs. +12.9%), supported by scale, value proposition and expanding omnichannel ecosystem.

    60% confidence

Data points we hold from this source

Walmart Inc. · stock return 1y17 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Top Analyst Reports for Amazon.com, Walmart & American Express — Source | Via News | ViaNews Market